HOME >> MEDICINE >> NEWS
Heart transplant survival: Results may be key to rejection prevention, detection, treatment

Research to be presented at the International Society for Heart and Lung Transplantation (ISHLT) 24th Annual Meeting April 21-24 in San Francisco, points to major victories in the battle for immune system balance in heart transplant patients.

"The combination of emerging technologies and drugs could mean greatly improved patient management and longer survival rates," said Mandeep Mehra, M.D., Program Chair of ISHLT and an ISHLT director. "The results of these studies have been much anticipated by the transplant community."

Some of the late-breaking trial results to be revealed include:

  • Use of intravascular ultrasound as a predictor for long-term heart transplant outcomes Data from a five-year multi-center validation study (Abstract #27)
  • Immunosuppressant drug everolimus used to prevent acute cardiac disease and rejection 24-month study results (Abstract #28)
  • Using molecular testing to predict clinical outcomes for heart transplantation Outcomes of a prospective multi-center trial (Abstract #192)
  • Protection from transplant disease (graft vasculopathy) with use of sirolimus from time of heart transplantation Results from a two-year study (Abstract #193)

Worldwide, approximately 4,500 cardiac transplants are performed annually. Despite significant progress made in surgical techniques and post-operative care, the risks associated with cardiac surgery remain high. The one-year survival rate after transplantation is approximately 80 percent; this number drops to nearly 50 percent after 10 years. The leading cause of death during the first three years is acute rejection of the transplanted organ. The patient's immune system attacks the heart as if it were a foreign object until it no longer functions properly.

Another contributing factor to limited survival rates is cardiac allograft vasculopathy (transplant vessel damage). This thickening of artery walls in a transplanted heart
'"/>

Contact: Kelly Goff
kellygoff@server63.com
210-378-1980
International Society for Heart and Lung Transplantation
19-Apr-2004


Page: 1 2

Related medicine news :

1. The European Society of Cardiology launches Women at Heart
2. Heart surgeons publish death rates
3. Heart attack treatment gap may be closing for women
4. The Larry King Cardiac Foundation presents The Changing Face of Heart Disease on Feb. 2
5. Brenner Childrens Hospital named to NIH Pediatric Heart Network
6. Heart patients treated by non-cardiologists less likely to receive medications
7. Heart failure patients treated for diabetes with insulin have increase in mortality
8. New research results: Heart jacket shown to be effective
9. Heart surgery patients receive less aggressive discharge care
10. Heart attack, stroke risk overlooked in diabetics
11. Heart arrhythmias easily treated, yet few know risks

Post Your Comments:
(Date:10/31/2014)... 31, 2014 At the start of ... narrowly escaping carbon monoxide poisoning in their homes. Now, ... away, one family-owned, Missouri-based heating and cooling company is ... sure families start the home heating season with the ... , Beginning Nov. 1, 2014, E and Q ...
(Date:10/31/2014)... UT (PRWEB) October 31, 2014 ... new Activz Silver line offering natural silver ... wipes. For over a century, silver has been used ... in Activz Silver products is the most advanced version ... has a unique chemical structure that supports the existing ...
(Date:10/31/2014)... 2014 (HealthDay News) -- Surgery for low back pain ... the United States you live, a new report says. ... back pain at some point in their lives, and ... care for a spine problem," co-author Brook Martin, of ... said in a college news release. In spinal ...
(Date:10/31/2014)... News) -- Obesity increases the risk of certain types ... two new U.S. studies show. One study of ... obese increased the risk for estrogen receptor-negative and progesterone ... this for a long time for white women, but ... study author Esther John, a senior research scientist at ...
(Date:10/31/2014)... insomnia is a major contributor to deaths caused by ... results underscore the importance of the "Sleep Well, Be ... , Results show that the risk of unintentional fatal ... of insomnia symptoms present. People with all three symptoms ... from a fatal injury than those with no insomnia ...
Breaking Medicine News(10 mins):Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Study Confirms Obesity-Breast Cancer Link for Blacks, Hispanics 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2
(Date:10/31/2014)... Oramed Pharmaceuticals Inc. (NASDAQCM: ... on the development of oral drug delivery systems, ... call to discuss the clinical results from its ... proprietary oral insulin capsules, to treat type 1 ... a.m. Eastern time. Shareholders and other ...
(Date:10/31/2014)... announces the list of stocks featured in the Analyst Blog. Every ... events impacting stocks and the financial markets. Stocks recently featured in ... Report ), Celgene (Nasdaq: CELG - Free Report ... ), Market Vectors Biotech ETF (AMEX: BBH - ... XBI - Free Report ). Today, Zacks is ...
(Date:10/31/2014)... , October 31, 2014 Multigate Medical ... patents of B. Braun Melsungen AG (B. Braun) by selling ... safety IV catheters manufactured by Poly Medicure Ltd (Polymed). The ... proceeding number VID 463 of 2013 can be ... detailed judgment, Multigate was found to have infringed claim 1 ...
Breaking Medicine Technology:Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 2The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 4The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 5The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 7B. Braun Wins Patent Disputes Against Poly Medicure Ltd's Australian Distributor Multigate Medical Devices Pty. Ltd. and Spanish Distributor Dextromédica S. L. 2
Cached News: